Anthony Best Dynamics supplies advanced testing systems to the global motor industry, for research and development and for production quality control.We design and manufacture specialised systems for:■ Kinematics and compliance testing■ Vehicle dynamics testing on the track■ Vehicle Dynamics / Driver in Loop Simulation■ Driver assistance system (ADAS) testing■ Autonomous vehicle testing■ Steering system testing■ Noise/vibration (NVH) testing of powertrain assemblies

Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease. Our pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.

Silence Therapeutics is a leading RNA technology company

We are a drug development company with a proprietary genetic medicine platform

Our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.  This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet clinical need. Silence’s technology is currently in the clinic in a Phase 2a pancreatic cancer trial.

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

Caledonia is an exploration, development and mining company focused on Southern Africa. Caledonia's primary asset is a 49% interest in the Blanket Mine in Zimbabwe which produced over 45,500 ounces of gold in 2013 at a cash cost of US$613/oz.Caledonia has a strong, experienced management team and Board of Directors with diverse expertise in gold production, exploration, mine development, finance and marketing.

Aus­tralian Secu­ri­ties Exchange listed Scot­gold Resources Lim­ited (ASX:SGZ) was estab­lished in 2007 and listed on the ASX in Jan­u­ary 2008. The company’s shares were admit­ted to trad­ing on the AIM mar­ket of the Lon­don Stock Exchange (AIM:SGZ) in Feb­ru­ary 2010. The Company’s prin­ci­pal objec­tive, since 2008, has been the advance­ment of the Conon­ish Gold and Sil­ver Project in Scotland’s Grampian High­lands to a pro­duc­tion deci­sion and explo­ration of the highly prospec­tive ten­e­ments com­pris­ing the Grampian Gold Project with the view of iden­ti­fy­ing fur­ther project opportunities.

Introducing Solo Oil

- Oil and gas Investment company- Listed on the London AiM Market (SOLO)

Objectives

To acquire and develop a diverse global portfolio of oil & gas assets

Portfolio

Non-operated oil & gas assets:

- Major stake in the prolific Ruvuma Basin, Tanzania- Interest in Kiliwani North (KNDL), Tanzania- More than 5 tcf of prospective resources identified in Tanzania- Ntorya-1 (Tanzania) discovery flowed 20 mmscfd and 139 bopd- Participation in UK Weald Basin exploration projects, including Horse Hill- Strategic investment in Burj Africa, West Africa- Enhanced Oil Recovery project in Ontario, Canada

Sound Energy is a well-funded Mediterranean upstream company, listed on AIM, with cost covering production, a cornerstone investor, a strategic partnership with Schlumberger (one of the largest companies in our sector) and an active and potentially transformational drill programme.

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

Kennedy Ventures plc is an investing company listed on AIM, focused on principally, but not exclusively, in the resources sector. The Company has made a first investment in African Tantalum (Pty) Ltd, a Namibian based operation producing tantalite concentrate. In view of the attractive opportunities in tantalum, the Company is likely to initially focus on related projects located in Southern Africa.

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

PrimaryBid the leading online equity funding platform, available on both web and mobile, that enables investors to gain access to placings, fundraisings and IPOs of AIM-listed companies. The platform is open to all investors and is supported by the broking community as a way of accessing, on behalf of their AIM clients seeking capital, the large and active private investor market, as well as institutions.  To date almost £37m has been sourced for issuers, via the platform.

Rockhopper Exploration plc ("Rockhopper") is an AIM listed oil and gas exploration company based in the UK with interests in the Falkland Islands.  It was established in 2004 with a strategy to invest in and undertake an offshore oil exploration programme.  It was floated on AIM in August 2005.

Rockhopper holds 40% interests in production licences PL032 and PL033 and, on completion of a farm-in announced in October 2013, 24% stakes in blocks PL004a, PL004b, and PL004c. All of these blocks are operated by Premier Oil. In addition, it has a 3% interest block PL003, operated by Falkland Oil and Gas.

In August 2014 Rockhopper completed the takeover of Mediterranean Oil & Gas plc ("MOG"). Through the acquisition of MOG, Rockhopper now holds a portfolio of production, development/appraisal and exploration interests in Italy, Malta and France.

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.